ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| CommonStock · Amount ($) · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Common Stock in Treasury · Treasury Amount ($) · Non-controlling Interest · Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance at September 30, 2025 | 138,363 | $231 | $2,139,725 | $6,443 | $(1,627,154) | (2,661) | $(53,193) | $37,364 | $503,416 | ||||
| Stock-based compensation | — | — | 19,371 | — | — | — | — | — | 19,371 | ||||
| Exercise of stock options | 296 | — | 5,098 | — | — | — | — | — | 5,098 | ||||
| Common stock - restricted stock units vesting | 704 | 1 | 1 | — | — | — | — | — | 2 | ||||
| Issuance of common stock under at-the-market offering, net of issuance costs | 689 | 1 | 46,831 | — | — | — | — | — | 46,832 | ||||
| Foreign currency translation adjustments | — | — | — | 110 | — | — | — | — | 110 | ||||
| Unrealized gains on available-for-sale securities, net | — | — | — | 146 | — | — | — | — | 146 | ||||
| Dividends declared by variable interest entity to noncontrolling shareholders | — | — | — | — | — | — | — | (40,520) | (40,520) | ||||
| Net income (loss) | — | — | — | — | 30,811 | — | — | (2,569) | 28,242 | ||||
| Balance at December 31, 2025 | 140,052 | $233 | $2,211,026 | $6,699 | $(1,596,343) | (2,661) | $(53,193) | $(5,725) | $562,697 | ||||
| Stock-based compensation | — | — | 16,670 | — | — | — | — | — | 16,670 | ||||
| Exercise of stock options | 121 | — | 1,968 | — | — | — | — | — | 1,968 | ||||
| Common stock - restricted stock units vesting | 1,043 | 1 | — | — | — | — | — | — | 1 | ||||
| Issuance of common stock in follow-on offering, net of issuance costs | 2,016 | 2 | 116,605 | — | — | — | — | — | 116,607 | ||||
| Issuance of pre-funded warrants | — | — | 99,998 | — | — | — | — | — | 99,998 | ||||
| Purchase of Capped Calls related to the 2026 Convertible Note | — | — | (47,880) | — | — | — | — | — | (47,880) | ||||
| Foreign currency translation adjustments | — | — | — | 990 | — | — | — | 990 | |||||
| Unrealized losses on available-for-sales securities | — | — | — | (6,934) | — | — | — | (6,934) | |||||
| Change in ownership interest in consolidated VIE | — | — | (3,120) | (13) | — | — | — | 3,133 | — | ||||
| Gain on VIE's sale of IPR&D assets | — | — | — | — | — | — | — | (7,629) | (7,629) | ||||
| Net loss | — | — | — | — | (132,732) | — | — | (4,840) | (137,572) | ||||
| Balance at March 31, 2026 | 143,232 | $236 | $2,395,267 | $742 | $(1,729,075) | (2,661) | $(53,193) | $(15,061) | $598,916 | ||||
| CommonStock | Amount ($) | AdditionalPaid-InCapital | Accumulated Other Comprehensive Income | AccumulatedDeficit | Common Stock in Treasury | Treasury Amount ($) | Non-controlling Interest | Total | |
|---|---|---|---|---|---|---|---|---|---|
| Balance at September 30, 2024 | 124,376 | $217 | $1,806,000 | $4,750 | $(1,625,523) | — | $— | $5,619 | $191,063 |
| Stock-based compensation | — | — | 15,209 | — | — | — | — | — | 15,209 |
| Exercise of stock options | 70 | — | 634 | — | — | — | — | — | 634 |
| Common stock - restricted stock units vesting | 209 | — | — | — | — | — | — | — | — |
| Issuance of pre-funded warrants | — | — | 25,000 | — | — | — | — | — | 25,000 |
| Foreign currency translation adjustments | — | — | — | (106) | — | — | — | — | (106) |
| Unrealized losses on available-for-sale securities, net | — | — | — | (507) | — | — | — | — | (507) |
| Net loss | — | — | — | — | (173,085) | — | — | (2,133) | (175,218) |
| Balance at December 31, 2024 | 124,655 | $217 | $1,846,843 | $4,137 | $(1,798,608) | — | $— | $3,486 | $56,075 |
| Stock-based compensation | — | — | 16,027 | — | — | — | — | — | 16,027 |
| Exercise of stock options | 353 | — | 2,619 | — | — | — | — | — | 2,619 |
| Common stock - restricted stock units vesting | 1,128 | 1 | — | — | — | — | — | — | 1 |
| Common stock issued | 11,926 | 12 | 241,375 | — | — | — | — | — | 241,387 |
| Foreign currency translation adjustments | — | — | — | (400) | — | — | — | — | (400) |
| Unrealized gains on available-for-sale securities | — | — | — | 653 | — | — | — | — | 653 |
| Net income (loss) | — | — | — | — | 370,445 | — | — | (2,582) | 367,863 |
| Balance at March 31, 2025 | 138,062 | $230 | $2,106,864 | $4,390 | $(1,428,163) | — | $— | $904 | $684,225 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.